Literature DB >> 27976420

Myopathology in congenital myopathies.

C A Sewry1,2, C Wallgren-Pettersson3.   

Abstract

Congenital myopathies are clinically and genetically a heterogeneous group of early onset neuromuscular disorders, characterized by hypotonia and muscle weakness. Clinical severity and age of onset are variable. Many patients are severely affected at birth while others have a milder, moderately progressive or nonprogressive phenotype. Respiratory weakness is a major clinical aspect that requires regular monitoring. Causative mutations in several genes have been identified that are inherited in a dominant, recessive or X-linked manner, or arise de novo. Muscle biopsies show characteristic pathological features such as nemaline rods/bodies, cores, central nuclei or caps. Small type 1 fibres expressing slow myosin are a common feature and may sometimes be the only abnormality. Small cores (minicores) devoid of mitochondria and areas showing variable myofibrillar disruption occur in several neuromuscular disorders including several forms of congenital myopathy. Muscle biopsies can also show more than one structural defect. There is considerable clinical, pathological and genetic overlap with mutations in one gene resulting in more than one pathological feature, and the same pathological feature being associated with defects in more than one gene. Increasing application of whole exome sequencing is broadening the clinical and pathological spectra in congenital myopathies, but pathology still has a role in clarifying the pathogenicity of gene variants as well as directing molecular analysis.
© 2016 British Neuropathological Society.

Entities:  

Keywords:  central nuclei; congenital myopathies; cores; fibre-type disproportion; myotubular; nemaline

Mesh:

Year:  2017        PMID: 27976420     DOI: 10.1111/nan.12369

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  16 in total

1.  Dysfunctional sarcomere contractility contributes to muscle weakness in ACTA1-related nemaline myopathy (NEM3).

Authors:  Barbara Joureau; Josine Marieke de Winter; Stefan Conijn; Sylvia J P Bogaards; Igor Kovacevic; Albert Kalganov; Malin Persson; Johan Lindqvist; Ger J M Stienen; Thomas C Irving; Weikang Ma; Michaela Yuen; Nigel F Clarke; Dilson E Rassier; Edoardo Malfatti; Norma B Romero; Alan H Beggs; Coen A C Ottenheijm
Journal:  Ann Neurol       Date:  2018-02-06       Impact factor: 10.422

2.  ACTN2 mutations cause "Multiple structured Core Disease" (MsCD).

Authors:  Xavière Lornage; Norma B Romero; Claire A Grosgogeat; Edoardo Malfatti; Sandra Donkervoort; Michael M Marchetti; Sarah B Neuhaus; A Reghan Foley; Clémence Labasse; Raphaël Schneider; Robert Y Carlier; Katherine R Chao; Livija Medne; Jean-François Deleuze; David Orlikowski; Carsten G Bönnemann; Vandana A Gupta; Michel Fardeau; Johann Böhm; Jocelyn Laporte
Journal:  Acta Neuropathol       Date:  2019-01-30       Impact factor: 17.088

3.  Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia.

Authors:  Takashi Kondo; Toshimichi Yasuda; Keiko Mukaida; Sachiko Otsuki; Rieko Kanzaki; Hirotsugu Miyoshi; Hiroshi Hamada; Ichizo Nishino; Masashi Kawamoto
Journal:  J Anesth       Date:  2018-01-17       Impact factor: 2.078

4.  Molecular Mechanisms of Muscle Weakness Associated with E173A Mutation in Tpm3.12. Troponin Ca2+ Sensitivity Inhibitor W7 Can Reduce the Damaging Effect of This Mutation.

Authors:  Yurii S Borovikov; Armen O Simonyan; Stanislava V Avrova; Vladimir V Sirenko; Charles S Redwood; Olga E Karpicheva
Journal:  Int J Mol Sci       Date:  2020-06-22       Impact factor: 5.923

5.  Inositol trisphosphate receptor-mediated Ca2+ signalling stimulates mitochondrial function and gene expression in core myopathy patients.

Authors:  Matteo Suman; Jenny A Sharpe; Robert B Bentham; Vassilios N Kotiadis; Michela Menegollo; Viviana Pignataro; Jordi Molgó; Francesco Muntoni; Michael R Duchen; Elena Pegoraro; Gyorgy Szabadkai
Journal:  Hum Mol Genet       Date:  2018-07-01       Impact factor: 6.150

6.  Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model.

Authors:  Anaïs Fongy; Sestina Falcone; Jeanne Lainé; Bernard Prudhon; Aurea Martins-Bach; Marc Bitoun
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

Review 7.  Nemaline myopathies: a current view.

Authors:  Caroline A Sewry; Jenni M Laitila; Carina Wallgren-Pettersson
Journal:  J Muscle Res Cell Motil       Date:  2019-06-21       Impact factor: 2.698

8.  Molecular Mechanisms of the Deregulation of Muscle Contraction Induced by the R90P Mutation in Tpm3.12 and the Weakening of This Effect by BDM and W7.

Authors:  Yurii S Borovikov; Daria D Andreeva; Stanislava V Avrova; Vladimir V Sirenko; Armen O Simonyan; Charles S Redwood; Olga E Karpicheva
Journal:  Int J Mol Sci       Date:  2021-06-12       Impact factor: 5.923

9.  Triggering typical nemaline myopathy with compound heterozygous nebulin mutations reveals myofilament structural changes as pathomechanism.

Authors:  Johan Lindqvist; Weikang Ma; Frank Li; Yaeren Hernandez; Justin Kolb; Balazs Kiss; Paola Tonino; Robbert van der Pijl; Esmat Karimi; Henry Gong; Josh Strom; Zaynab Hourani; John E Smith; Coen Ottenheijm; Thomas Irving; Henk Granzier
Journal:  Nat Commun       Date:  2020-06-01       Impact factor: 14.919

10.  Nebulin nemaline myopathy recapitulated in a compound heterozygous mouse model with both a missense and a nonsense mutation in Neb.

Authors:  Jenni M Laitila; Elyshia L McNamara; Catherine D Wingate; Hayley Goullee; Jacob A Ross; Rhonda L Taylor; Robbert van der Pijl; Lisa M Griffiths; Rachel Harries; Gianina Ravenscroft; Joshua S Clayton; Caroline Sewry; Michael W Lawlor; Coen A C Ottenheijm; Anthony J Bakker; Julien Ochala; Nigel G Laing; Carina Wallgren-Pettersson; Katarina Pelin; Kristen J Nowak
Journal:  Acta Neuropathol Commun       Date:  2020-02-17       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.